ARID1A is altered in 27.98% of bladder urothelial carcinoma patients [2].

ARID1A is an inclusion eligibility criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ARID1A status and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

ATM is altered in 11.08% of bladder urothelial carcinoma patients [2].

ATM is an inclusion eligibility criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ATM status and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

ATR is altered in 5.92% of bladder urothelial carcinoma patients [2].

ATR is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ATRX is altered in 5.75% of bladder urothelial carcinoma patients [2].

ATRX is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATRX status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BARD1 is altered in 2.74% of bladder urothelial carcinoma patients [2].

BARD1 is an inclusion eligibility criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BARD1 status and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

BRCA1 is altered in 6.0% of bladder urothelial carcinoma patients [2].

BRCA1 is an inclusion eligibility criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 status and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

BRCA2 is altered in 8.26% of bladder urothelial carcinoma patients [2].

BRCA2 is an inclusion eligibility criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA2 status and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

BRIP1 is altered in 3.3% of bladder urothelial carcinoma patients [2].

BRIP1 is an inclusion eligibility criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRIP1 status and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

C11orf30 is altered in 1.07% of bladder urothelial carcinoma patients [2].

C11orf30 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains C11orf30 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK12 is altered in 6.16% of bladder urothelial carcinoma patients [2].

CDK12 is an inclusion eligibility criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK12 status and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

CHEK1 is altered in 1.29% of bladder urothelial carcinoma patients [2].

CHEK1 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK1 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CHEK2 is altered in 3.76% of bladder urothelial carcinoma patients [2].

CHEK2 is an inclusion eligibility criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CHEK2 status and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

ERCC2 is altered in 11.82% of bladder urothelial carcinoma patients [2].

ERCC2 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC2 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERCC3 is altered in 1.73% of bladder urothelial carcinoma patients [2].

ERCC3 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC3 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERCC4 is altered in 2.36% of bladder urothelial carcinoma patients [2].

ERCC4 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC4 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERCC5 is altered in 1.71% of bladder urothelial carcinoma patients [2].

ERCC5 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC5 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERCC6 is altered in 1.06% of bladder urothelial carcinoma patients [2].

ERCC6 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC6 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCA is altered in 5.28% of bladder urothelial carcinoma patients [2].

FANCA is an inclusion eligibility criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FANCA status and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

FANCB is altered in 1.35% of bladder urothelial carcinoma patients [2].

FANCB is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCB status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCC is altered in 1.79% of bladder urothelial carcinoma patients [2].

FANCC is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCC status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCD2 is altered in 7.05% of bladder urothelial carcinoma patients [2].

FANCD2 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCD2 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCE is altered in 2.35% of bladder urothelial carcinoma patients [2].

FANCE is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCE status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCF is altered in 1.84% of bladder urothelial carcinoma patients [2].

FANCF is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCF status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCG is altered in 1.8% of bladder urothelial carcinoma patients [2].

FANCG is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCG status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCI is altered in 2.91% of bladder urothelial carcinoma patients [2].

FANCI is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCI status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCL is altered in 1.79% of bladder urothelial carcinoma patients [2].

FANCL is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCL status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCM is altered in 6.76% of bladder urothelial carcinoma patients [2].

FANCM is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCM status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR1 is altered in 3.62% of bladder urothelial carcinoma patients [2].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 0 are open and 1 is closed. Of the trial that contains FGFR1 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2/phase 3 (0 open) [3].

FGFR2 is altered in 2.48% of bladder urothelial carcinoma patients [2].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FGFR3 is altered in 26.68% of bladder urothelial carcinoma patients [2].

FGFR3 is an inclusion eligibility criterion in 2 clinical trials for bladder urothelial carcinoma, of which 1 is open and 1 is closed. Of the trials that contain FGFR3 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2/phase 3 (0 open) [3].

HDAC1 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC1 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

HDAC2 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC2 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MDM2 is altered in 9.16% of bladder urothelial carcinoma patients [2].

MDM2 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MDM4 is altered in 1.23% of bladder urothelial carcinoma patients [2].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLF1 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLF1 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLH1 is altered in 2.2% of bladder urothelial carcinoma patients [2].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLH3 is altered in 3.06% of bladder urothelial carcinoma patients [2].

MLH3 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH3 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MRE11A is altered in 1.3% of bladder urothelial carcinoma patients [2].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH2 is altered in 3.33% of bladder urothelial carcinoma patients [2].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH3 is altered in 2.37% of bladder urothelial carcinoma patients [2].

MSH3 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH6 is altered in 3.82% of bladder urothelial carcinoma patients [2].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MUTYH is altered in 1.53% of bladder urothelial carcinoma patients [2].

MUTYH is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MUTYH status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NBN is altered in 2.56% of bladder urothelial carcinoma patients [2].

NBN is an inclusion eligibility criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NBN status and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

NPM1 is altered in 0.61% of bladder urothelial carcinoma patients [2].

NPM1 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PALB2 is altered in 3.35% of bladder urothelial carcinoma patients [2].

PALB2 is an inclusion eligibility criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PALB2 status and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

PARP1 is altered in 2.12% of bladder urothelial carcinoma patients [2].

PARP1 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PARP2 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PMS1 is altered in 2.41% of bladder urothelial carcinoma patients [2].

PMS1 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS1 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PMS2 is altered in 2.72% of bladder urothelial carcinoma patients [2].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

POLE is altered in 5.91% of bladder urothelial carcinoma patients [2].

POLE is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PPP2R1A is altered in 2.05% of bladder urothelial carcinoma patients [2].

PPP2R1A is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PPP2R1A status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PPP2R2A is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PPP2R2A status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD50 is altered in 3.09% of bladder urothelial carcinoma patients [2].

RAD50 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD50 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51 is altered in 0.75% of bladder urothelial carcinoma patients [2].

RAD51 is an inclusion eligibility criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51 status and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

RAD51B is altered in 1.21% of bladder urothelial carcinoma patients [2].

RAD51B is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51B status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51C is altered in 2.7% of bladder urothelial carcinoma patients [2].

RAD51C is an inclusion eligibility criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51C status and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

RAD51D is altered in 0.47% of bladder urothelial carcinoma patients [2].

RAD51D is an inclusion eligibility criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD51D status and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

RAD54L is altered in 1.5% of bladder urothelial carcinoma patients [2].

RAD54L is an inclusion eligibility criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RAD54L status and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

SLX4 is altered in 6.15% of bladder urothelial carcinoma patients [2].

SLX4 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SLX4 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SMARCB1 is altered in 1.99% of bladder urothelial carcinoma patients [2].

SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

STAG2 is altered in 12.93% of bladder urothelial carcinoma patients [2].

STAG2 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains STAG2 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

STK11 is altered in 1.65% of bladder urothelial carcinoma patients [2].

STK11 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains STK11 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TSC1 is altered in 9.71% of bladder urothelial carcinoma patients [2].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TSC2 is altered in 3.8% of bladder urothelial carcinoma patients [2].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

XRCC1 is altered in 4.05% of bladder urothelial carcinoma patients [2].

XRCC1 is an inclusion eligibility criterion in 1 clinical trial for bladder urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC1 status and bladder urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].